Alvine pharmaceuticals reports positive results with alv003 in phase 1 trial of therapy in development for celiac disease
Alvine Pharmaceuticals, Inc., today announced proof of concept in a Phase 1 Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800 mg of ALV003 were safe and tolerable in healthy volunteers. (Source: Health News from Medical News Today) MedWorm Sponsored Message: Get support for celiac disease, gluten free recipes, and moderated discussions by
joining the active community at The Sensible Celiac.
http://www.medicalnewstoday.com/articles/127534.php
